XOMA CorpDUS XOMA Stock Report

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The firm has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. The company also acquires the economics associated with pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm has a portfolio of more than 70 assets. Its royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087), a clinical-stage anti-IL-1b product candidate; scalimab (CFZ533); mezagitamab (TAK-079); RZ358; AZD2936, a TIGIT/PD-1 bispecific antibody; MK-4830, and others. The Company’s portfolio also includes Ebopiprant (OBE022), an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.